hydralazine

基本解釋

There was no significant difference of p-ERK expression between SHR hydralazine group and SHR sham group (P>0.05).4.
SHR肼苯噠嗪組和SHR未治療組大鼠心肌p-ERK表達(dá)無明顯差異(P>0.;05)。
By contrast, hydralazine increased cardiac index by 58 percent and decreased systemic vascular resistence by 40 percent.
相比之下，使用肼苯達(dá)嗪，心臟指數(shù)增加58%25，而全身血管阻力減少40%25。
The preferred agents are methyldopa for prolonged antenatal therapy, and hydralazine, labetalol or nifedipine for peripartum treatment of acute hypertensive episodes.
長期產(chǎn)前治療首選的藥物是甲基多巴，圍產(chǎn)期急性高血壓發(fā)作的治療可用拉貝洛爾或心痛定。
However,in spite of the effect of lowering blood pressure,hydralazine did not prevent or regress cardiac hypertrophy and did not decrease the level of p-ERK and BNP in SHR.
而降壓效果相似的肼苯噠嗪不能抑制心肌肥厚，對p-ERK和BNP水平?jīng)]有影響，提示BNP水平可以反映逆轉(zhuǎn)心肌肥厚藥物療效。
Thus the five groups were: (1) low salt only, (2) low salt plus grape powder, (3) high salt only, (4) high salt plus grape powder, and (5) high salt plus vasodilator hydralazine.
這五組是：（1）單純低鹽組，（2）低鹽+葡萄粉組，（3）單純高鹽組，（4）高鹽組+葡萄粉組，（5）高鹽組+擴(kuò)管藥肼苯噠嗪組。